Ran Nussbaum
InvestorPartner at Pontifax Venture Capital
Israel
Writes $10M – $50M checks · typically $25M
About
Managing partner and co-founder of The Pontifax Group. Has served on boards of numerous biotech companies including Kite Pharma, cCAM Therapeutics, ArQule, Emergence, and Prevail, and currently chairs Graviton, Lutris Pharma, and Adcytherix.
Contact· self-published, not guessed
Experience
- Pontifaxpartnercurrent2004 — present
Investments
Board seats
Graviton Bioscience CorporationLB PharmaceuticalsUrogen
Per SEC Form D filings.
Colleagues at Pontifax Venture Capital
Asaf Shinar
Director at Pontifax Venture Capital
Iyona Rajkomar
Partner at Pontifax Venture Capital
Lina Kaminski
Principal at Pontifax Venture Capital
Momi Karako
Investment Professional at Pontifax Venture Capital
Ohad Hammer
Investment Professional at Pontifax Venture Capital
Silvia Noiman
Venture Partner at Pontifax Venture Capital
Tomer Kariv
Chief Executive Officer at Pontifax Venture Capital
Frequently asked questions
- Who is Ran Nussbaum?
- Managing partner and co-founder of The Pontifax Group. Has served on boards of numerous biotech companies including Kite Pharma, cCAM Therapeutics, ArQule, Emergence, and Prevail, and currently chairs Graviton, Lutris Pharma, and Adcytherix.
- Where does Ran Nussbaum work?
- Ran Nussbaum is Partner at Pontifax Venture Capital.
- What check size does Ran Nussbaum write?
- Ran Nussbaum typically writes checks of $10M – $50M.
- What boards does Ran Nussbaum sit on?
- Ran Nussbaum holds tracked board seats at Graviton Bioscience Corporation, LB Pharmaceuticals, Urogen.
- Where did Ran Nussbaum go to school?
- Ran Nussbaum studied at ygal alon.